These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
201 related articles for article (PubMed ID: 8686979)
1. Prostate cancer: emerging concepts. Part II. Garnick MB; Fair WR Ann Intern Med; 1996 Aug; 125(3):205-12. PubMed ID: 8686979 [TBL] [Abstract][Full Text] [Related]
2. Prostate cancer: emerging concepts. Part I. Garnick MB; Fair WR Ann Intern Med; 1996 Jul; 125(2):118-25. PubMed ID: 8678366 [TBL] [Abstract][Full Text] [Related]
3. Management of localised prostate cancer: watchful waiting, surgery or radiation therapy, depending on the natural course, which is often relatively slow. Prescrire Int; 2012 Oct; 21(131):242-8. PubMed ID: 23185849 [TBL] [Abstract][Full Text] [Related]
4. Undetectable prostate specific antigen at 6-12 months: a new marker for early success in hormonally treated patients after prostate brachytherapy. Miller N; Smolkin ME; Bissonette E; Theodorescu D Cancer; 2005 Jun; 103(12):2499-506. PubMed ID: 15852361 [TBL] [Abstract][Full Text] [Related]
5. Patient selection, cancer control, and complications after salvage local therapy for postradiation prostate-specific antigen failure: a systematic review of the literature. Nguyen PL; D'Amico AV; Lee AK; Suh WW Cancer; 2007 Oct; 110(7):1417-28. PubMed ID: 17694553 [TBL] [Abstract][Full Text] [Related]
6. Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): an open-label, randomised, phase 3 factorial trial. Denham JW; Joseph D; Lamb DS; Spry NA; Duchesne G; Matthews J; Atkinson C; Tai KH; Christie D; Kenny L; Turner S; Gogna NK; Diamond T; Delahunt B; Oldmeadow C; Attia J; Steigler A Lancet Oncol; 2014 Sep; 15(10):1076-89. PubMed ID: 25130995 [TBL] [Abstract][Full Text] [Related]
7. Medical therapy of prostate cancer. A review. Roscigno M; Sangalli M; Mazzoccoli B; Scattoni V; Da Pozzo L; Rigatti P Minerva Urol Nefrol; 2005 Jun; 57(2):71-84. PubMed ID: 15951731 [TBL] [Abstract][Full Text] [Related]
17. High-dose radiation employing external beam radiotherapy and high-dose rate brachytherapy with and without neoadjuvant androgen deprivation for prostate cancer patients with intermediate- and high-risk features. Vargas C; Martínez A; Galalae R; Demanes J; Harsolia A; Schour L; Nuernberg N; Gonzalez J Prostate Cancer Prostatic Dis; 2006; 9(3):245-53. PubMed ID: 16786040 [TBL] [Abstract][Full Text] [Related]
18. Randomized comparative study of 3 versus 8-month neoadjuvant hormonal therapy before radical prostatectomy: biochemical and pathological effects. Gleave ME; Goldenberg SL; Chin JL; Warner J; Saad F; Klotz LH; Jewett M; Kassabian V; Chetner M; Dupont C; Van Rensselaer S; J Urol; 2001 Aug; 166(2):500-6; discussion 506-7. PubMed ID: 11458055 [TBL] [Abstract][Full Text] [Related]
19. Phase I-II trial evaluating combined intensity-modulated radiotherapy and in situ gene therapy with or without hormonal therapy in treatment of prostate cancer-interim report on PSA response and biopsy data. Teh BS; Ayala G; Aguilar L; Mai WY; Timme TL; Vlachaki MT; Miles B; Kadmon D; Wheeler T; Caillouet J; Davis M; Carpenter LS; Lu HH; Chiu JK; Woo SY; Thompson T; Aguilar-Cordova E; Butler EB Int J Radiat Oncol Biol Phys; 2004 Apr; 58(5):1520-9. PubMed ID: 15050332 [TBL] [Abstract][Full Text] [Related]
20. Effect of neoadjuvant androgen deprivation on circulating prostate cells in the bone marrow of men undergoing radical prostatectomy. Wood DP; Beaman A; Banerjee M; Powell I; Pontes E; Cher ML Clin Cancer Res; 1998 Sep; 4(9):2119-23. PubMed ID: 9748128 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]